JohnA.KeechJr.DO

Clinical Trials

• Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28

  Completed

  Phase 3

• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06

  Active, not recruiting

  Phase 3

• S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23

  Active, not recruiting

  Phase 3

• Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Start of enrollment: 2013 Jun 01

  Completed

  Phase 3

• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15

  Active, not recruiting

  Phase 3

• Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01

  Terminated

  Phase 2

• Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Start of enrollment: 2014 Jun 01

  Completed

  Not Applicable

• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08

  Completed

• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25

  Completed

  Phase 2

• Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01

  Completed

  Phase 3

• Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19

  Recruiting

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18

  Active, not recruiting

  Phase 3

• Join now to see all